Quarterly report pursuant to Section 13 or 15(d)

4. STOCKHOLDERS' EQUITY (Tables)

v3.5.0.2
4. STOCKHOLDERS' EQUITY (Tables)
9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
Schedule of assumptions used for equity compensation expense
    Nine Months Ended     Nine Months Ended  
    September 30, 2016     September 30, 2015  
Expected term   5.8-6.3 years     6.3 years  
Volatility     51-52%       51-57%  
Dividend yield     0.0       0.0  
Risk-free interest rate     1.54-1.79%       1.49-2.14%  
Schedule of stock options outstanding
    Nine Months Ended  
    September 30, 2016  
          Weighted  
          Average  
          Exercise  
    Shares     Price  
             
Outstanding at beginning of period     1,464,203     $ 8.02  
Forfeited     (21,334 )   $ 8.02  
Expired     (8,666 )   $ 7.88  
Granted     100,984     $ 6.20  
Outstanding at end of period and expected to vest     1,535,187     $ 7.90  
Options exercisable     1,102,900     $ 7.54  
Stock-based compensation expense
    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2016     2015     2016     2015  
                         
Research and development   $ 95,076     $ 184,302     $ 383,909     $ 514,107  
Plasma centers     15,289       12,457       40,044       35,813  
General and administrative     152,598       251,173       572,135       671,742  
                                 
Total stock-based compensation expense   $ 262,963     $ 447,932     $ 996,088     $ 1,221,662